FibroGen

FGEN NASDAQ
43.53
-1.34
-2.99%
Closed 16:29 08/22 EDT
Open
45.71
Prev Close
44.87
High
45.71
Low
43.45
Volume
456.89K
Avg Vol (3M)
624.45K
52 Week High
61.95
52 Week Low
33.51
% Turnover
0.53%
Market Cap
3.78B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers FibroGen FGEN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
MORE >

Recently

Name
Price
%Change